Boston (April 29, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq"). This notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq's Listing Rule 5550(a)(2) (the "Bid Price Rule"). Na ...

Boston (April 17, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1). On February 1, 2024, Allarity Therapeutics presented a strategic plan to the Nasdaq Hearings Panel, detailing both immediate and long-term strategies aimed at regaining compliance with th ...

Allarity Therapeutics (NASDAQ:ALLR) stock is heading higher on Friday alongside heavy pre-market trading.Investors will note that this movement comes after the company announced a prospectus supplement. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is elig ...

Boston (April 4, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 9:30 a.m. Eastern Time on April 9, 2024. The Company's common stock will begin trading on a split-adjusted basis wh ...

Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive AdvisorReduced Net Loss from Operations by 50% and Reduced Net Loss by 26%Announced Data in December 2023 from Advanced Ovarian Cancer Phase 2 Stenoparib Study Showing Significant Clinical Benefit Boston (March 8, 2024) — Allarity Therapeutics, Inc. ("Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer tre ...

Financial Performance - Allarity Therapeutics reduced net loss from operations by 50% to $17.1 million in 2023, compared to $34 million in 2022[7] - The company achieved a net loss of $11.9 million for 2023, a decrease of 26% from $16.1 million in 2022[7] - Research and Development (R&D) expenses increased slightly to $7.1 million in 2023 from $6.9 million in 2022[7] - General and Administrative (G&A) expenses remained stable at $10.0 million for both 2023 and 2022[7] Clinical Development - Early data from the Phase 2 study of stenoparib indicated significant clinical benefit, with 5 evaluable patients showing stable disease and 1 achieving a complete response[3] - The company plans to announce interim data from the DRP-guided Phase 2 clinical trial of stenoparib in advanced ovarian cancer in Q2 2024[6] - The DRP platform has shown a statistically significant prediction of clinical outcomes in 37 out of 47 studies examined[8] - Allarity is focused on addressing unmet medical needs in oncology, particularly through the development of stenoparib[9] Leadership and Structure - Leadership changes include the appointment of Thomas Jensen as Interim CEO and Jeremy Graf, Ph.D., as Executive Advisor[5] - The company is headquartered in the U.S. with a research facility in Denmark, emphasizing its commitment to cancer treatment innovation[9] Financial Position - Total current assets decreased from $4,968 million in 2022 to $1,971 million in 2023, a decline of approximately 60%[18] - Total liabilities increased from $12,654 million in 2022 to $14,613 million in 2023, an increase of about 15.5%[18] - The accumulated deficit rose from $82,550 million in 2022 to $94,451 million in 2023, reflecting an increase of approximately 14.5%[19] - The total stockholders' deficit increased significantly from $113 million in 2022 to $2,751 million in 2023[19] - The company reported a liquidation preference of $17.54 for Series A Preferred Stock as of December 31, 2023[18] - Additional paid-in capital increased from $83,158 million in 2022 to $90,369 million in 2023, a growth of about 8.6%[19] - The number of shares issued and outstanding for Common Stock decreased from 11,356 in 2022 to 5,886,934 in 2023[19] - Intangible assets increased from $9,549 million in 2022 to $9,871 million in 2023, a rise of approximately 3.4%[18] - The company had a cash balance of $166 million as of December 31, 2023, down from $2,029 million in 2022, a decrease of about 91.8%[18] - The current liabilities increased from $11,222 million in 2022 to $14,167 million in 2023, an increase of approximately 26.5%[18]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 87-2147982 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission file num ...

Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024. Thomas Jensen, CEO and co-founder of Allarity, will present the company's novel work in developing the drug- specific Drug Response Predictor (DRP®) companion diagnostics (CDx) platform. This work spans from cancer cell line research ...

Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024. Thomas Jensen, CEO and co-founder of Allarity, will present the company's novel work in developing the drug-specific Drug Response Predictor (DRP®) companion diagnostics (CDx) platform. This work spans from cancer cell line research t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41160 ALLARITY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | |-----------------------------------------|-------| | Del ...